Velano Vascular Named to 2017 FierceMedTech’s “Fierce 15”

- Innovative PIVO™ needle free blood draw technology combats growing vascular access challenge for patients, practitioners and health systems -

SAN FRANCISCO, Dec. 12, 2017 (GLOBE NEWSWIRE) -- Velano Vascular today announced that it was named by FierceMedTech as one of 2017’s Fierce 15 med tech companies, acknowledging the company as one of the most promising private companies in the industry for its breakthrough work addressing the world’s growing vascular access challenges.

More than one billion inpatient blood draws occur around the world every year, informing nearly 70% of all medical decisions. However, the rising incidence of aging, obesity and chronic illness is making venous access more difficult and less effective. This phenomenon, known as Difficult Venous Access (DVA), is estimated to affect more than 30% of all patients worldwide.

“Venous access is fundamental to a hospital stay, yet it is managed through outdated and antiquated technologies that produce painful, risky and inefficient outcomes,” said Velano Vascular Chief Executive Eric M. Stone. “Access is increasingly one of the more urgent but unheralded medical issues of our time. It is vital that we deliver breakthrough technologies and procedures that advance a more humane, effective standard of care.” 

Velano’s pioneering technologies are ushering in a new standard of care for vascular access in hospitals. The company’s FDA-cleared PIVO device enables high quality blood draws from indwelling peripheral IV lines, and is currently in use at a number of leading health systems around the country.

PIVO is the first of two technologies currently available to U.S. hospitals from the company’s growing family of access products. Velano is investing in a series of novel and necessary products related to blood collection, vascular access, and infection prevention.

The Fierce 15 celebrates the spirit of being “fierce” – championing innovation and creativity, even in the face of intense competition.  This is FierceMedTech’s sixth annual Fierce 15 selection. Every year FierceMedTech evaluates hundreds of private companies from around the world for its annual Fierce 15 list, which is based on a variety of factors such as the strength of its technology, partnerships, venture backers and a competitive market position.

Joining Velano Vascular on this year’s list is CardioFocus, Guardant Health, and Livogno, amongst others. To learn more about Velano Vascular and PIVO, visit

About FierceMedTech
FierceMedTech keeps biopharma executives, device developers, engineers, and researchers updated on the must-know news, trends and developments in medical devices and diagnostics. More than 90,000 top industry professionals rely on FierceMedicalTech for an insider briefing on the day's top stories.

About Velano Vascular
Velano is committed to reducing the pain, risk, and inefficiencies of vascular access and blood collection. The PIVO device enables blood draws from Peripheral IV lines, aiming to enable more compassionate care for hospital inpatients, a safer practice for caregivers, and a more financially responsible alternative for health systems. Headquartered in San Francisco, CA, Velano is backed by a number of notable venture firms, hospital and health system investors, and dozens of health-industry veterans. More information is available at and @velanovascular.

For Press: 
Michael Azzano
Cosmo PR for Velano Vascular

Rebecca Friend